Clinical Trials | August 18, 2022
Sanofi updates on amcenestrant clinical development program
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
The decision is based on the outcome of a prespecified interim analysis of the Phase 3 AMEERA-5 trial
The study concluded that elevated levels of two proteins help predict how a person will recover from a traumatic brain injury (TBI), providing important information to determine appropriate care
The OAI classification implies that the US FDA may withhold approval of any pending product applications or supplements filed from this facility till the outstanding observations are resolved
Collaboration supports multiple discovery efforts, including vaccines
First PARP inhibitor to demonstrate clinical benefit in radiographic progression-free survival in combination with a new hormonal agent with or without homologous recombination repair gene mutations
The Trial, the first of its kind in Israel, recently obtained approval from the Israeli Ministry of Health and is preparing for participant recruitment.
Quetiapine Extended-Release Tablets are indicated for the treatment of Schizophrenia, Bipolar disorder and adjunctive treatment of Major Depressive Disorder (MDD)
The card-to-cloud device was launched into the U.S. and many other markets and is designed to work without an embedded communications module.
The estimated capex is to the tune of Rs. 140 crore to be funded through debt and internal accrual
The company has reported total income of Rs. 450.26 crores during the period ended June 30, 2022.
Subscribe To Our Newsletter & Stay Updated
